Case 3: Rapidly Progressing Stage IV NSCLC Following Immuno-Chemotherapy

Stanford Cancer Institute Breakthroughs in Cancer: Luis Diaz, MDПодробнее

Case 2: Treatment Considerations in Stage IV NSCLCПодробнее

Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic LandscapeПодробнее

Case 3: Second-Line Therapy After Chemo/I-O in Stage IV NSCLCПодробнее

NSCLC: Treating Progression After Chemo and I-OПодробнее

Case 3: Considerations for Second-Line Therapy in Stage IV NSCLCПодробнее

Facilitating Progress in the Treatment of SCLCПодробнее

Case 3: Chemoimmunotherapy in SCLCПодробнее

Case Based Panel Discussion - Rapid Progression Adenocarcinoma High PD-L1 - How Do You Treat?Подробнее

Case 3: Tissue & Plasma Sampling in Stage IV NSCLCПодробнее

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLCПодробнее

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) | OncotargetПодробнее

Immunotherapy and Chemotherapy in Second-Line NSCLCПодробнее

Case Based Panel Discussion - Stage 3 NSCLC Best Schedule - Durvalumab/Imfinzi in Varying PatientsПодробнее

Combined immuno-chemotherapy improves survival and responses in metastatic lung cancerПодробнее

Case 4: Treating Stage IV NSCLC With Novel ApproachesПодробнее

Understanding Lung Cancer Survival RateПодробнее

Selective Inhibition of Oncogenic Transcription and Other Approaches in the Treatment of SCLCПодробнее

Going from Stage IV Lung Cancer to Clean ScansПодробнее

Case 2: Biomarkers and Treatment Decisions in Stage IV NSCLCПодробнее